What Has Been the Progress and Growth of the Ovulation Inducing Drugs Market in Recent Years?
The ovulation inducing drugs market has seen considerable growth due to a variety of factors.
• The market for ovulation-inducing drugs has seen significant expansion recently. It is predicted to climb from $4.42 billion in 2024 to $4.74 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.3%.
Factors influencing this growth during the past periods include the evolution of clomiphene citrate, the launch of letrozole, regularization and standardization, as well as the arrival of ovulation predictor kits.
How Does the Forecast Look for the Ovulation Inducing Drugs Market?
The ovulation inducing drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market for ovulation stimulating medications is predicted to experience robust growth in the coming years, reaching $6.12 billion by 2029 with a compound annual growth rate (CAGR) of 6.6%.
The projected growth for this period can be traced back to several factors such as evolving lifestyle patterns and postponed parenthood, incorporation of digital health, broadening market penetration, increasing infertility rates, and tailored treatment protocols. Upcoming trends within this forecast period encompass customized treatment methods, advancements in the field of reproductive endocrinology, non-intrusive fertility tracking, a growing demand for assisted reproductive techniques, and the creation of innovative drug formulations.
What Are The Leading Drivers Of Growth In The Ovulation Inducing Drugs Market?
An uptick in incidences of female infertility is predicted to bolster the progress of the ovulation-inducing drugs market. The term 'female infertility' pertains to a physiological state wherein a woman is unable to become pregnant or maintain a pregnancy to full term, despite regular unprotected sexual intercourse over a long time frame, generally one year or more. To address irregular or missng ovulation issues, ovulation-inducing medications are utilized to manage this form of infertility. These treatments interact with the hormonal pathways involved in ovulation, prompting the ovaries to expel matured eggs. For example, the US government agency, Centers for Disease Control and Prevention suggest that in 2022, there will be 6.1 million females aged between 15 and 44 in the US struggling with conception, accounting for 10% of all females. Furthermore, according to data from the US medical management firm, CCRM Management Company LLC, in June 2022, 1 in 4 couples worldwide typically face issues with infertility, increasing by 5% to 10% annually. As a result, the ovulation-inducing drug market is developing due to the growing prevalence of female infertility. Ovulation Inducing Drugs Market Driver: Surge In Patients Choosing Ivf In The Ovulation Inducing Drugs Market
How Are The Segments Defined Within The Global Ovulation Inducing Drugs Market?
The ovulation inducing drugs market covered in this report is segmented –
1) By Drug Class: Hormones, Therapeutics Drugs
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Hormones: Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors
2) By Therapeutic Drugs: Metformin, Letrozole, Bromocriptine
Pre-Book The Ovulation Inducing Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Ovulation Inducing Drugs Industry?
Leading enterprises in the ovulation-inducing drugs market are working on innovative drugs like Cetrorelix acetate and securing permission to administer these drugs to women undertaking controlled ovarian stimulation. Cetrorelix acetate is an injectable gonadotropin-releasing hormone (GnRH) foe that prevents early ovulation in females undergoing in vitro fertilization (IVF). For example, in August 2022, Akorn Operating Company LLC, a pharmaceutical firm from the US, got FDA accreditation for a generic variant of the cetrorelix acetate injection, 0.25 mg (Cetrorelix). This is the first AP-rated bioequivalent to Merck Serono's Cetrotide that has received permission. Cetrorelix acetate, being a GnRH antagonist, functions by obstructing the impacts of the gonadotropin-releasing hormone (GnRH). GnRH stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Furthermore, the drug helps avoid premature LH spikes in women who are undergoing controlled ovarian stimulation (COS) and ensures that all the eggs get an opportunity to develop.
Who Are the Key Players In The Ovulation Inducing Drugs Market?
Major companies operating in the ovulation inducing drugs market report are:
• Pfizer Inc.
• Johnson And Johnson Pvt Ltd.
• Merck And Co. Inc.
• Abbvie Inc.
• Novartis AG
• Bayer AG
• Sanofi SA
• Abbott Laboratories
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceutical Inc.
• Mylan N.V
• Astellas Pharma Inc.
• Sun Pharmaceuticals Industries Ltd.
• Aurobindo Pharma Limited
• Dr Reddy's Laboratories Ltd.
• Intas Pharmaceuticals Limited
• Endo International Inc.
• Ferring Pharmaceuticals Inc.
• Lupin Limited
• LIVZON Pharmaceutical Group Inc.
• Torrent Pharmaceuticals Ltd.
• Gedeon Richter PLC
• Glenmark Pharmaceuticals Ltd.
• Fresenius Kabi AG
• Zydus Pharmaceuticals (USA) Inc.
• Serum Institute of India Ltd.
• EMD Serono Inc.
• Cipla Inc.
What Is The Most Dominant Region In The Ovulation Inducing Drugs Market?
North America was the largest region in the ovulation-inducing drugs market in 2024. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
